SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): December 20, 2006
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-22705
|
|
33-0525145 |
| (State or other
|
|
(Commission File
|
|
(IRS Employer Identification |
| jurisdiction of
|
|
Number)
|
|
No.) |
| incorporation or |
|
|
|
|
| organization) |
|
|
|
|
| |
|
|
| 12790 El Camino Real
|
|
92130 |
| (Address of principal executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 617-7600
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4 (c))
TABLE OF CONTENTS
ITEM 8.01 OTHER EVENTS.
On December 20, 2006, the Company announced that under the collaboration between Neurocrine and
GlaxoSmithKline (GSK), GSK has initiated Phase II “proof of concept” clinical trials with a lead
Corticotropin Releasing Factor R1 (CRF1) receptor antagonist compound for two
indications, social anxiety disorder (SocAD) and irritable bowel syndrome (IBS). As a result, the
Company has recognized an $8 million milestone payment from GSK upon initiation of these two Phase
II clinical trials.
Item 9.01. Exhibits
| 99.1 |
|
Press release dated December 20, 2006. |